公开(公告)号：US09625357B2

公开(公告)日：2017-04-18

申请号：US14003189

申请日：2012-03-08

Applicant: Avishay Bransky ,  Liron Shlomo

Inventor： Avishay Bransky ,  Liron Shlomo

IPC: G01N1/00 ,  G01N1/20 ,  B01L3/00

CPC classification number: G01N1/2035 ,  B01L3/502723 ,  B01L3/50273 ,  B01L3/502738 ,  B01L2200/0621 ,  B01L2200/0689 ,  B01L2300/044 ,  B01L2300/087 ,  B01L2300/123 ,  B01L2400/0481 ,  B01L2400/0683 ,  G01N33/86

Abstract: The invention discloses a disposable cartridge for preparing a sample fluid containing cells for analysis. The cartridge comprises one or more parallel preparation units, each preparation unit comprises one or more chambers enclosed between seals and connected in series. Each chamber is configured for receiving an input fluid, performing a procedure affecting the fluid thereby generating an output fluid, and releasing the output fluid. A first chamber of the one or more chambers is a pressable chamber coupled to a first opening, while a last chamber of the one or more chambers is coupled to a second opening. The input fluid of the first chamber is the sample fluid. The one or more preparation units are coupleable to a compartment for performing analysis of the respective output fluids convey able via the second openings.

公开(公告)号：US20170089889A1

公开(公告)日：2017-03-30

申请号：US15283828

申请日：2016-10-03

Applicant: Abbott Laboratories ,  Abbott Japan Co. Ltd.

Inventor： Toru Yoshimura ,  Kenju Fujita ,  Barry L. Dowell

IPC: G01N33/53 ,  G01N33/86 ,  G01N33/574

CPC classification number: G01N33/5306 ,  G01N33/57423 ,  G01N33/86 ,  G01N2333/5758

Abstract: To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample.By using a blood sample in a condition in which a blood coagulation factor is not activated is used as a sample, the degradation of ProGRP is suppressed, whereby it is possible to store a sample for a long period of time and to improve the accuracy of an assay.

公开(公告)号：US09599623B2

公开(公告)日：2017-03-21

申请号：US14124533

申请日：2012-06-05

Applicant: Suzette Chance ,  Gian Paolo Visentin

Inventor： Suzette Chance ,  Gian Paolo Visentin

IPC: G01N33/558 ,  G01N33/68 ,  G01N33/86

CPC classification number: G01N33/6854 ,  G01N33/558 ,  G01N33/6863 ,  G01N33/86 ,  G01N2800/32

Abstract: The present invention provides a novel assay for detecting human antibodies specific for a platelet factor 4 (PF4)/heparin complex in a fluid sample. The assay utilizes an immobilized PF4/polyanion complex and an anti-human antibody conjugated to a non-particulate fluorescent dye to capture and detect human PF4/heparin antibodies. Various devices, methods and systems based on the disclosed PF4/heparin assay are also provided.

公开(公告)号：US20160376634A1

公开(公告)日：2016-12-29

申请号：US15038819

申请日：2014-11-25

Applicant: OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU "GEMATOLOGICHESKAYA KORPORATSIYA"

Inventor： Vladimir Nikolaevich KOLYADKO ,  Fazoil Inoyatovich ATAULLAKHANOV ,  Mikhail Aleksandrovich PANTELEEV ,  Tatyana Alekseevna VUYMO ,  Ruzanna Armenovna OVSEPYAN ,  Stepan Sergeevich SUROV ,  Vera Anatoljevna KORNEEVA

IPC: C12Q1/56 ,  C07K14/81

CPC classification number: C12Q1/56 ,  A61K38/57 ,  C07K14/435 ,  C07K14/43563 ,  C07K14/81 ,  C07K14/811 ,  C07K14/8135 ,  G01N33/86 ,  G01N2333/96458

Abstract: The present invention relates to medicine, and specifically to hematology, and can be used in particular for diagnostic and research purposes when determining coagulation characteristics of blood and its components, and also in biotechnology and fundamental biological research.One of the aspects of the present invention is a polypeptide for inhibition of contact activation in a sample of blood or its product to be tested, which comprises the sequence of an infestin-4 mutant MutB (SEQ ID NO: 1) and which substantially corresponds thereto, where said sequence can have modifications outside the area of the inhibitory loop which significantly maintain the activity of the said polypeptide, which acts as a high-selectivity fXIIa inhibitor, the selectivity of which is higher than that of native infestin-4 and Mut15, or the activity of which is higher than that of native infestin-4 and Mut15.Another aspect of the invention is the use of the said polypeptide to study the coagulation in the test sample of blood or its product, including at least one of the following steps, and preferably all of the following steps: obtaining a sample, bringing it into contact with the said polypeptide, and incubating the resulting mixture, bringing a blood coagulation activator into contact with the sample containing the said polypeptide, and measuring the coagulation parameters of the sample.Yet another aspect of the invention is the use of a polypeptide comprising the sequence of an infestin-4 mutant MutB as an anticoagulant which blocks contact activation by means of bringing s sample into contact with the said polypeptide for collection purposes and in order to increase the storage time of the sample.

Abstract translation: 本发明的另一方面是使用包含infestin-4突变MutB的序列的多肽作为抗凝血剂，其通过使s样品与所述多肽接触以阻止接触活化用于收集目的，并且为了增加 样品的储存时间。

公开(公告)号：US20160370392A1

公开(公告)日：2016-12-22

申请号：US15249599

申请日：2016-08-29

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Thomas Meyer ,  Gottlieb Schacher ,  Rolf Sigrist ,  Christian Guzek

IPC: G01N35/00

CPC classification number: G01N35/0092 ,  G01N33/86 ,  G01N35/026 ,  G01N35/1002 ,  G01N35/1065 ,  G01N2035/00356 ,  G01N2035/00524 ,  G01N2035/0094 ,  Y10T436/113332 ,  Y10T436/114165 ,  Y10T436/115831 ,  Y10T436/2575

Abstract: A method and system for automatic in-vitro diagnostic analysis are described. The method comprises adding a first reagent type and a second reagent type to a first test liquid during a first and second cycle times respectively. The addition of the first reagent type to the first test liquid comprises parallel addition of a second reagent type to a second test liquid during the first cycle time. The addition of the second reagent type to the first test liquid comprises parallel addition of a first reagent type to a third test liquid during the second cycle time, respectively.

公开(公告)号：US20160363600A1

公开(公告)日：2016-12-15

申请号：US14902547

申请日：2014-06-26

Applicant: University of Washington

Inventor： Nathan J. SNIADECKI ,  Nathan J. WHITE ,  Ari KARCHIN ,  Lucas H. TING

IPC: G01N33/86 ,  B01L3/00

CPC classification number: G01N33/86 ,  B01L3/502715 ,  B01L3/502738 ,  B01L3/502746 ,  B01L3/502761 ,  B01L2300/025 ,  B01L2300/027 ,  B01L2300/0627 ,  B01L2300/0663 ,  B01L2300/0819 ,  B01L2300/0832 ,  B01L2300/0887 ,  B01L2300/123 ,  B01L2400/0487 ,  B01L2400/086 ,  G01N2800/224

Abstract: The present technology relates generally to fluidics devices for measuring platelet coagulation and associated systems and methods. In some embodiments, a fluidics device includes an array of microstructures including pairs of generally rigid blocks and generally flexible posts. The fluidics device further includes at least one fluid channel configured to accept the array. The fluidics device can further include a measuring element configured to measure a degree of deflection of one or more of the flexible posts in the array. In some embodiments, the fluidics device comprises a handheld device and usable for point of care testing of platelet forces and coagulation.

Abstract translation: 本技术一般涉及用于测量血小板凝结的流体装置及其相关系统和方法。 在一些实施例中，流体装置包括一组微结构，包括一对通常刚性的块和通常柔性的柱。 流体装置还包括配置成接受阵列的至少一个流体通道。 流体装置还可以包括测量元件，其被配置成测量阵列中的一个或多个柔性柱的偏转程度。 在一些实施例中，流体装置包括手持装置，并且可用于血小板力和凝血的护理点测试。

公开(公告)号：US20160341747A1

公开(公告)日：2016-11-24

申请号：US14974619

申请日：2015-12-18

Applicant: Imigene, Inc.

Inventor： Matt Ewert

IPC: G01N33/86 ,  G01N21/3577 ,  G01N21/59

CPC classification number: G01N33/86 ,  G01N21/3577 ,  G01N21/59

Abstract: Provided herein are kits, devices and methods related to blood analysis. In some aspects, kits, devices and methods related to analyzing unprocessed and processed blood are provided, e.g., by processing blood with enzymes and measuring transmittance of light passed through the processed blood and as well as through unprocessed blood. Such kits, devices and methods are useful, e.g., for identifying the presence or absence of infection, and also the type of infection, if present.

Abstract translation: 本文提供了与血液分析相关的试剂盒，装置和方法。 在一些方面，例如通过用酶处理血液并测量通过经处理的血液的光的透射率以及通过未加工的血液来提供与分析未加工和加工的血液相关的试剂盒，装置和方法。 这样的试剂盒，装置和方法是有用的，例如用于鉴定感染的存在或不存在，以及感染的类型（如果存在）。

公开(公告)号：US20160326568A1

公开(公告)日：2016-11-10

申请号：US14966296

申请日：2015-12-11

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Friedrich Ackermann ,  Andreas Calatzis

IPC: C12Q1/56

CPC classification number: C12Q1/56 ,  C12Y304/21006 ,  G01N33/86 ,  G01N2333/96444 ,  G01N2496/00 ,  G01N2500/20

Abstract: The present invention concerns diagnostic methods for coagulation testing involving determining anticoagulant activity elicited by a first anticoagulant in a sample comprising measuring a first Factor Xa activity in a body fluid test sample of said subject, measuring a second Factor Xa activity in at least one calibrator sample comprising a predefined anticoagulation activity for a second anticoagulant, calculating an universal parameter for the anticoagulation activity comprised in the test sample based on the first and the second measured Factor Xa activities and comparing the said parameter for the anticoagulation activity with predefined ranges of expected anticoagulation activity for at least three anticoagulants. Further provided is a computer program code assisting the method as well as a system for carrying out the said method as well as a kit.

Abstract translation: 本发明涉及用于凝固测试的诊断方法，其涉及确定样品中第一抗凝血剂引起的抗凝血活性，包括测量所述受试者的体液测试样品中的第一因子Xa活性，测量至少一个校准品样品中的第二因子Xa活性 包括针对第二抗凝血剂的预定抗凝活性，基于第一和第二测量的因子Xa活动计算包含在测试样品中的抗凝活性的通用参数，并将抗凝活性的所述参数与预期的抗凝活性预定范围进行比较 至少有三种抗凝剂。 还提供了一种辅助该方法的计算机程序代码以及用于执行所述方法的系统以及套件。

公开(公告)号：US20160305966A1

公开(公告)日：2016-10-20

申请号：US15102944

申请日：2014-12-09

Applicant: DSM IP ASSETS B.V.

Inventor： Abel FERRANDEZ ,  Anne BRISSET

IPC: G01N33/86

CPC classification number: G01N33/86 ,  G01N2333/745 ,  G01N2333/96433 ,  G01N2333/96444 ,  G01N2333/974

Abstract: The present invention is directed to a novel method of determining inhibitors of proteolytically active coagulation factors, referred to herein as anticoagulants, in a sample, in particular the qualitative detection of direct thrombin and factor Xa inhibitors in a sample. The method of the present invention allows a qualitative determination of the nature anticoagulants present in a sample. This can be achieved with only one coagulation-based test. The method can be used in a test kit, including a point-of-care system.

Abstract translation: 本发明涉及一种测定样品中蛋白水解活性凝血因子抑制剂（本文称为抗凝血剂）的新方法，特别是样品中直接凝血酶和因子Xa抑制剂的定性检测。 本发明的方法允许定性测定样品中存在的天然抗凝剂。 这可以通过仅一次凝血试验来实现。 该方法可用于测试工具包，包括护理点系统。

公开(公告)号：US09459248B2

公开(公告)日：2016-10-04

申请号：US14295116

申请日：2014-06-03

Applicant: Abbott Laboratories

Inventor： Toru Yoshimura ,  Kenju Fujita ,  Barry L. Dowell

IPC: G01N33/86 ,  G01N33/53 ,  G01N33/574

CPC classification number: G01N33/5306 ,  G01N33/57423 ,  G01N33/86 ,  G01N2333/5758

Abstract: To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample. By using a blood sample in a condition in which a blood coagulation factor is not activated is used as a sample, the degradation of ProGRP is suppressed, whereby it is possible to store a sample for a long period of time and to improve the accuracy of an assay.

Abstract translation: 通过提高已知在生物样品中不稳定的ProGRP的稳定性来提供更方便和更准确的测定ProGRP的方法。 通过使用血液凝固因子未活化的状态下的血液样品作为样品，可以抑制ProGRP的降解，能够长时间存储样品，提高准确度 一个测定。